This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

The Run-Up Trade: Biodel's Insulin Trial Results

DANBURY, Conn. ( TheStreet) -- Biodel (BIOD - Get Report) is nearing completion of a mid-stage study of its latest mealtime injectable insulin, giving traders an opportunity to once again profit from a run-up into a very important event for the drug maker.

I say "once again" because veteran traders rode the Biodel roller coaster in 2010 when the stock almost doubled in price leading up to an FDA approval decision for the injectable insulin product Linjeta. When FDA rejected Linjeta, Biodel shares tanked.

Biodel gave up on Linjeta and went back to its labs to develop a new mealtime insulin. The result is BIOD-123, which is designed to reach the bloodstream faster with fewer injection site reactions. Biodel believes BIOD-123 will demonstrate comparable glycemic control but with less weight gain and a lower incidence of hypoglycemia (low blood sugar) compared to other mealtime insulins.

Patient enrollment in a phase II study of BIOD-123 was completed on March 28, according to Biodel. The treatment period is 18 weeks, so I expect the last patient to complete the study in the beginning of August. Assuming 4-8 weeks for data gathering and analysis, Biodel should announce results from the study in September. Biodel has said it expects to announce top-line results in the third quarter.

The market is starting to take notice of Biodel again the BIOD-123 phase II results near. Institutional and private equity ownership in the company has nearly doubled in the past two quarters and now totals 75% of outstanding shares. Biodel's market cap today is only $52 million compared to MannKind's (MNKD) nearly $2 billion market value. That's a valuation gap which should narrow as we get closer to the BIOD-123 study results.

If even a small amount of the hype and market inflation helping MannKind today leaks over to Biodel, shares will move higher this summer. As always, run-up traders should exit their Biodel positions before September to avoid the risk of owning the stock when the BIOD-123 data are released.

Messier is long Biodel.

Mark Messier is the founder of BioRunUp.com. Messier is a DOJ-certified Criminal Intelligence Analyst and former IT professional, specializing in law enforcement applications. In 2008, Messier began trading biotech stocks, using his analytical expertise to detect and capitalize on human and market patterns. Starting with only $2,200 in his trading account, he has booked over $400,000 in profit in just 4 years. In April 2010, Messier founded the subscription-based stock-trading web site BioRunUp.com to share his biotech trading ideas with the online investor community. Messier enjoys spending time with his wife and two young boys and visiting his "home away from home" in Costa Rica.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
BIOD $1.36 0.00%
MNKD $6.52 0.00%
AAPL $128.46 0.00%
FB $78.97 0.00%
GOOG $558.40 0.00%

Markets

DOW 18,132.70 -81.72 -0.45%
S&P 500 2,104.50 -6.24 -0.30%
NASDAQ 4,963.5270 -24.3630 -0.49%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs